Key clinical point: Pre-existing radiographic damage was substantially prevalent in patients with psoriatic arthritis (PsA), with secukinumab therapy being associated with the inhibition of joint tenderness and swelling; however, high baseline radiographic damage reduced the likelihood of achieving minimal disease activity (MDA).
Major finding: Overall, 86% and 60% of patients had erosion and joint space narrowing (JSN) scores of >0, respectively. At week 16 and 52, 150 and 300 mg secukinumab reduced tender and swollen joint counts across all values of baseline erosion and JSN scores; however, patients with higher baseline erosion and JSN scores were less likely to achieve MDA.
Study details: This was a post hoc analysis of two phase 3 trials, FUTURE 1 and FUTURE 5 , including 1554 patients with PsA who received 300 or 150 mg secukinumab with or without a loading dose.
Disclosures: This study received funding from Novartis Pharma AG. Four authors declared being employees of or owning stocks in Novartis. Seven authors declared ties with various sources, including Novartis.
Source: Mease P et al. Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis. Arthritis Res Ther. 2022;24(1):283 (Dec 28). Doi: 10.1186/s13075-022-02944-1